We reviewed the evidence on proton pump inhibitors (PPIs) and dementia. PPIs are among the most widely utilized drugs in the world. Dementia affects roughly 5% of the population of the United States (US) and world aged 60 years and older. With respect to PPIs and dementia, basic research has suggested plausible mechanisms but descriptive and analytic epidemiological studies are not inconsistent. In addition, a single large-scale randomized trial showed no association. When the evidence is incomplete, it is appropriate for clinicians and researchers to remain uncertain. Regulatory or public health authorities sometimes need to make real-world decisions based on real-world data. When the evidence is complete, then the most rational judgments for individual patients the health of the general public are possible At present, the evidence on PPIs and dementia suggests more reassurance than alarm. Further large-scale randomized evidence is necessary to do so.

我们回顾了质子泵抑制剂（PPI）和痴呆症的证据。 PPI 是世界上使用最广泛的药物之一。痴呆症影响着美国和世界 60 岁及以上人口的大约 5%。关于质子泵抑制剂和痴呆症，基础研究提出了合理的机制，但描述性和分析性流行病学研究并不不一致。此外，一项大规模随机试验显示没有关联。当证据不完整时，临床医生和研究人员最好保持不确定性。监管或公共卫生当局有时需要根据真实世界的数据做出真实的决策。当证据完整时，就可以对个体患者和公众的健康做出最理性的判断。目前，关于 PPI 和痴呆症的证据表明更多的是安慰而不是警报。为此，需要进一步的大规模随机证据。